Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit-Reference-Cited by-同舟云学术

Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit

Published:2017-12 Issue:4 Volume:16 Page:372-376
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Tampellini Marco,Di Maio Massimo,Baratelli Chiara,Anania Lorenzo,Brizzi Maria Pia,Sonetto Cristina,La Salvia Anna,Scagliotti Giorgio Vittorio

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference15 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

2. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study;de Gramont;J Clin Oncol,1997

3. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study;Tournigand;J Clin Oncol,2004

4. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer;Loupakis;N Engl J Med,2014

5. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive and Prognostic Role of Systemic Immune-Inflammation Index (SII) in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil;Biomedicines;2024-09-11

2. Rationale and design of the COPERNIC Trial: a study of on-treatment ctDNA changes in chemo-refractory colorectal cancer patients;Clinical Colorectal Cancer;2024-09

3. Encorafenib plus cetuximab in patients with BRAFV600E-mutated metastatic colorectal cancer — Polish multicenter experience;Oncology in Clinical Practice;2024-08-21

4. Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer;Journal of Experimental & Clinical Cancer Research;2024-07-11

5. Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence;Future Oncology;2024-06-11